|
|
|
|
|
12.05.26 - 17:03
|
BanyanGlobal Names Stephan Roche Managing Partner (Business Wire)
|
|
|
Former Walton Family Enterprises CEO and Cascade executive to lead firm's next chapterBOSTON--(BUSINESS WIRE)--BanyanGlobal Family Business Advisors today announced that partner Stephan Roche has been elected Managing Partner. The appointment comes as Banyan continues to expand its work with complex, multigenerational family enterprises navigating succession, governance, and long-term ownership strategy.
Roche is a leading authority on family offices and multigenerational enterprises, with nearly two decades of experience advising globally dispersed families. Before joining Banyan as a partner, he served as CEO of Walton Enterprises, the family office for the Walton family, and as Chief Operating Officer of Cascade Asset Management, the investment office for Bill Gates and the Gates Foundation—two of the most prominent and sophisticated family offices in the world.
At Banyan, Roche works at the intersection of ownership, governance, and family dynamics—helping families navigate succession, align acro...
|
|
|
12.05.26 - 13:54
|
US-Iran Ceasefire Remains Fragile; Starmer Intends to Stay as PM; CPI | Bloomberg Brief 5/12/2026 (Bloomberg)
|
|
|
Oil rises and US equity futures fall as President Trump says the ceasefire between the US and Iran is on "life support." UK Prime Minister Keir Starmer tells his Cabinet he will not step down without a fight and intends to stay in power. John Cortese of Apollo Asset Management discusses the credit market with Bloomberg's Francine Lacqua at the JPMorgan Global Markets Conference. Kallum Pickering of Peel Hunt looks ahead to the CPI data. Matt Sause, CEO of Roche Diagnostics, joins as the firm's blood test for Alzheimer's disease wins EU approval. (Source: Bloomberg)...
|
|
|
|
|
12.05.26 - 07:03
|
Roche receives CE mark for new blood test to detect Alzheimer′s pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) (GlobeNewswire EN)
|
|
|
Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and designed to measure the phosphorylated Tau (pTau) 217 protein, an indicator of amyloid pathology and a hallmark of Alzheimer's disease.1,2,4,7,8 The same cutoffs (high and low) of the blood test can be used across primary and secondary care settings, to rule in or rule out amyloid pathology in people presenting with symptoms or complaints of cognitive decline.1,2,4,5 The early detection of the amyloid pathology is critical for Alzheimer's diagnosis and treatment, as it enables individuals, families, and caregivers to understand the cause of symptoms, access appropriate care, and actively contribute to the planning of next steps.3,4,5,9,10...
|
|
|
|
|
08.05.26 - 00:48
|
Live from DoubleLine Capital | The Close 5/7/2026 (Bloomberg)
|
|
|
Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are DoubleLine Global Sovereign & Emerging Markets Head Bill Campbell, GTCR Co-CEO Collin Roche, DoubleLine Non-Agency Residential Mortgage-Backed Securities Head Ken Shinoda, Cambridge Associates' Samantha Davidson, DoubleLine Deputy CIO Jeffrey Sherman, DoubleLine Global Developed Credit Director Robert Cohen, Man Group CEO Robyn Grew, & DoubleLine CEO & CIO Jeffrey Gundlach. (Source: Bloomberg)...
|
|
|
07.05.26 - 22:18
|
PE Risk Is Being Priced in a More Rational Way, GTCR′s Roche Says (Bloomberg)
|
|
|
GTCR Co-CEO and Managing Director Collin Roche reflects on the private equity landscape, emphasizing the importance of value creation over merely capitalizing on rising prices. Roche highlights GTCR's multibillion-dollar exit from Worldpay as a prime example of their strategy: backing executive teams to implement operational and strategic changes that improve business performance and justify higher exit multiples. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.05.26 - 07:03
|
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics (GlobeNewswire EN)
|
|
|
Basel, 7 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry. This acquisition builds on the successful partnership between Roche and PathAI, established in 2021 and scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms. Subject to the closing of the transaction, which is expected in the second half of the year, the acquired entity will become part of the Diagnostics division....
|
|
|
|
|
|
|
04.05.26 - 12:48
|
Roche Underperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Roche nach Zahlen auf "Underperform" mit einem Kursziel von 230 Franken belassen. Der Pharmakonzern werde weiterhin mit einem Aufschlag von etwa einem Viertel gegenüber vergleichbaren ......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
